Target intelligence / Profile preview

S-adenosylmethionine (SAM)

Target
SAM
Molecular classification
Other (coenzyme/cofactor, metabolite), Other (sulfonium compound)
01

Overview

S-adenosylmethionine (SAM) is a naturally occurring sulfonium compound formed from methionine and ATP. It is the principal biological methyl donor, essential for over 40 methylation reactions involving nucleic acids, proteins, lipids, and secondary metabolites. Most SAM is synthesized and consumed in the liver, where it plays key roles in transmethylation, transsulfuration, and aminopropylation, influencing processes such as gene expression, detoxification, and antioxidant defense. Commercially, it is known as SAMe and used as a dietary supplement. SAM's therapeutic use has been explored in liver disease, depression, and osteoarthritis, but clinical benefits remain inconclusive, and its long-term safety profile has not been fully established. SAM is not itself a drug target (e.g., receptor, enzyme, transporter), but rather a coenzyme and metabolite; enzymes that synthesize or utilize SAM are the actual molecular targets in drug discovery and pharmacology.

Other names
SAMeSAM-eAdoMetS-adenosyl-L-methionineAdemetionineMethionine,activeS-(5'-Adenosyl)methionine
02

Mechanism of action

Serves as a methyl donor in transmethylation reactions, Essential for the synthesis of cysteine and glutathione, Involved in the regulation of membrane lipid methylation

03

Biological functions

Methyl group donor in methylation reactionsPrecursor in transsulfuration and aminopropylationCofactor in the biosynthesis of numerous moleculesRegulation of gene expressionRedox balancingDetoxificationSignal transductionProtein repairCellular growth and repair
04

Disease associations

Liver diseases (especially cholestasis, cirrhosis)Neuropsychiatric disorders (depression)OsteoarthritisPotential role in circadian rhythm disordersCancer (methionine cycle dysregulation)
05

Safety considerations

Generally safe short-term, but long-term risks are unclearcaution in bipolar disorder (possible induction of mania)not well-studied in pregnancypossible toxicity with excessive use (affecting methylation balance and nucleotide metabolism)
06

Biomarkers

Reduced levels may indicate impaired liver function or metabolic disorders; occasionally monitored in research/clinical settings in the context of liver disease

Beyond the preview

Go deeper on S-adenosylmethionine (SAM).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on S-adenosylmethionine (SAM).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call